Menu
Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 2
A comparative study of DNA damage in patients suffering from diabetes and thyroid dysfunction and complications
Published 22 September 2010 Volume 2010:2 Pages 199—205
DOI https://doi.org/10.2147/CPAA.S11366
Review by Single anonymous peer review
Peer reviewer comments 2
Nima V Thakkar, Sunita M Jain
Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, Gujarat, India
Objective: The apoptotic DNA levels in blood leukocytes of patients with type 2 diabetes (T2D) and thyroid dysfunction were evaluated.
Materials and methods: Single-cell gel electrophoresis (comet assay) detects migration of DNA from individual cell nuclei following alkaline treatment. Comet assay pattern was studied in individuals with T2D, hypothyroid (HT), hyperthyroid (HeT), and patients suffering from both diabetes mellitus and HT (HT + DM). Results were compared with the normal subjects (n = 9 in each group). The percentage apoptotic cells were calculated from the tail length.
Results: T2D patients showed 92.24% of cell damage compared to HT or HeT patients (51.04% or 54.64%, respectively). Further, increase in cell damage was also observed in HT + DM subjects (P < 0.05). Pharmacologic therapy significantly influenced cell damage. However, age and duration of disease did not show any definite influence on apoptosis.
Conclusion: Dependence of disease seems to be the major contributor of the cell damage. However, thyroid dysfunction did not show any deleterious effects on individual cells under the study.
Keywords: comet assay, type 2 diabetes, hypothyroid, apoptosis
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.